International Journal of Chinese Medicine

| Peer-Reviewed |

Effect of a Herbal Formula Song Zhi Wan on Non-alcoholic Fatty liver Disease in Obese Mice

Received: 29 March 2021    Accepted: 14 April 2021    Published: 26 April 2021
Views:       Downloads:

Share This Article

Abstract

Background: Effective treatment against non-alcoholic fatty liver disease (NAFLD) is lacking. Song Zhi Wan (SZW), a Chinese formulation medicine comprising eight herbal ingredients, has been demonstrated to confer a liver protective effect in chronic hepatitis C patients. We aimed to investigate the effect of SZW on NAFLD using a high-fat diet (HFD; 60% fat) induced obese mouse model. Methods: C57BL/6J mice were fed with HFD for 10 weeks, followed by daily oral administration of various dosages of SZW (low [n=6], normal [n=10], high [n=10]) or water (n=10) for 8 weeks. Another formulation of SZW (modified SZW), in which two ingredients were replaced by radish seed and barley, was tested. Serum total cholesterol and triglyceride levels, liver transaminases, and histologic steatosis were assessed. Results: At the end of experiment, the HFD-fed placebo mice had a mean increase in serum total cholesterol and triglyceride by 57.7% and 35.0%, respectively. HFD-fed mice receiving either SZW formulation had a smaller increase in serum total cholesterol (mean increase 7.9% – 39.4%) and a significant reduction in triglyceride (mean reduction 4.2% – 27.4%; P < 0.05). A dosage dependent effect on serum total cholesterol and triglyceride was observed with modified SZW (=0.043 and 0.006, respectively). 90% of placebo mice and 59% of SZW-treated mice had severe steatosis (P=0.079). With an escalating dosage of original SZW, there was a decreasing proportion of mice with severe steatosis (P=0.013). Conclusion: SZW administration can attenuate hypercholesterolemia, reduce dyslipidemia and alleviate steatosis in HFD-induced obese mice.

DOI 10.11648/j.ijcm.20210502.11
Published in International Journal of Chinese Medicine (Volume 5, Issue 2, June 2021)
Page(s) 22-28
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Dyslipidemia, Herbal Medicine, Liver Steatosis, Non-alcoholic Fatty Liver Disease, Obese Mice

References
[1] Lonardo A, Byrne CD, Caldwell SH, Cortez-Pinto H, Targher G. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 1388-9.
[2] Seto WK, Yuen MF. Nonalcoholic fatty liver disease in Asia: emerging perspectives. J Gastroenterol 2017; 52: 164-74.
[3] Li Z, Xue J, Chen P, Chen L, Yan S, Liu L. Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of published studies. J Gastroenterol Hepatol 2014; 29: 42-51.
[4] Guo JS, Wang XJ, Wu CR, Liu XY, Li JP. Experimental research of songzhi pills on inducement of interferon in mice and rats. China J Chin Materia Medica (Zhongguo Zhong Yao Za Zhi) 2003; 28: 257-9. [Article in Chinese, English abstract].
[5] Xu J-l, Sheng G-g, Li X-d. Observation of curative effect on chronic Hepatitis C treated by Songzhi pill. Hubei J Trad Chin Med 2007; 29: 12-13. [Article in Chinese; http://caod.oriprobe.com/articles/12174267/Observation_of_Curative_Effect_on_Chronic_Hepatitis_C_Treated_by_Songz.htm].
[6] Liu X, Wang H, Meng W, Liu F, Deng D, Meng Y. Efficiacy of Song Zhi Wan in the treatment of chronic hepatitis C: clinical observation of 124 cases. Hunan J Trad Chin Med 2003; 19: 10-11. [Article in Chinese; http://eng.oversea.cnki.net/kcms/detail/detail.aspx?filename=HNZO200305006&DBName=cjfqtotal&dbcode=cjfq&uid=WEEvREcwSlJHSldSdmVqMDh6a1dqZUdqY3Q2cFVrZ010L0wzRDNEOGFrOD0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!].
[7] Liu X, (inventor); Xiangtan City Mongolian Chinese Herbal Medicine Institute of Liver Diseases, (assignee). Songzhi pill. China patent CN1130210C. 2003; https://patents.google.com/patent/CN1130210C/en; December 10, 2013.
[8] Song Zhi Wan. China Tailing (Changsha) Pharmaceutical Group. National Medical Products Adminstration, Registration Number Z20113065. http://english.nmpa.gov.cn/ and http://app1.sfda.gov.cn/datasearchcnda/face3/dir.html?type=yp; Approval Date: August 22, 2016.
[9] Wang CY, Liao JK. A mouse model of diet-induced obesity and insulin resistance. Methods Mol Biol 2012; 821: 421-33.
[10] Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
[11] Lee SJ, Oh PS, Lim KT. Hepatoprotective and hypolipidaemic effects of glycoprotein isolated from Gardenia jasminoides Ellis in mice. Clin Exp Pharmacol Physiol 2006; 33: 925-33.
[12] Chen YH, Lan T, Li J, Qiu CH, Wu T, Gou HJ, et al. Gardenia jasminoides attenuates hepatocellular injury and fibrosis in bile duct-ligated rats and human hepatic stellate cells. World J Gastroenterol 2012; 18: 7158-65.
[13] Dong H, Lu FE, Zhao L. Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease. Chin J Integr Med 2012; 18: 152-60.
[14] Lin CC, Lee HY, Chang CH, Yang JJ. The anti-inflammatory and hepatoprotective effects of fractions from Cudrania cochinchinensis var. gerontogea. Am J Chin Med 1999; 27: 227-39.
[15] Kim JH, Sim HA, Jung DY, Lim EY, Kim YT, Kim BJ, et al. Poria cocus Wolf Extract Ameliorates Hepatic Steatosis through Regulation of Lipid Metabolism, Inhibition of ER Stress, and Activation of Autophagy via AMPK Activation. Int J Mol Sci 2019; 20: 4801.
[16] Sun SS, Wang K, Ma K, Bao L, Liu HW. An insoluble polysaccharide from the sclerotium of Poria cocos improves hyperglycemia, hyperlipidemia and hepatic steatosis in ob/ob mice via modulation of gut microbiota. Chin J Nat Med 2019; 17: 3-14.
[17] Hu XY, Shu XC, Guo Y, Ma Y. Effect of an Ilex asprella root decoction on the related genes of lipid metabolism from chronic stress and hyperlipidemic fatty liver in rats. Chin Med J (Engl) 2012; 125: 3539-42.
[18] Hong M, Li S, Wang N, Tan HY, Cheung F, Feng Y. A Biomedical Investigation of the Hepatoprotective Effect of Radix salviae miltiorrhizae and Network Pharmacology-Based Prediction of the Active Compounds and Molecular Targets. Int J Mol Sci 2017; 18: 620.
[19] Lee HS, Son WC, Ryu JE, Koo BA, Kim YS. Standardized Salvia miltiorrhiza extract suppresses hepatic stellate cell activation and attenuates steatohepatitis induced by a methionine-choline deficient diet in mice. Molecules 2014; 19: 8189-211.
[20] Wang W, Xu AL, Li ZC, Li Y, Xu SF, Sang HC, et al. Combination of Probiotics and Salvia miltiorrhiza Polysaccharide Alleviates Hepatic Steatosis via Gut Microbiota Modulation and Insulin Resistance Improvement in High Fat-Induced NAFLD Mice. Diabetes Metab J 2020; 44: 336-348.
[21] Ye Z, Huang Q, Ni HX, Wang D. Cortex Lycii Radicis extracts improve insulin resistance and lipid metabolism in obese-diabetic rats. Phytother Res 2008; 22: 1665-70.
[22] Lu S, Zhang T, Gu W, Yang X, Lu J, Zhao R, et al. Volatile Oil of Amomum villosum Inhibits Nonalcoholic Fatty Liver Disease via the Gut-Liver Axis. Biomed Res Int 2018; 2018: (Article ID 3589874) 1-16.
Cite This Article
  • APA Style

    Danny Ka-Ho Wong, Saisai Zhang, Gerald Wong, Ching Yan Serene Cheng, Regina Cheuk-Lam Lo, et al. (2021). Effect of a Herbal Formula Song Zhi Wan on Non-alcoholic Fatty liver Disease in Obese Mice. International Journal of Chinese Medicine, 5(2), 22-28. https://doi.org/10.11648/j.ijcm.20210502.11

    Copy | Download

    ACS Style

    Danny Ka-Ho Wong; Saisai Zhang; Gerald Wong; Ching Yan Serene Cheng; Regina Cheuk-Lam Lo, et al. Effect of a Herbal Formula Song Zhi Wan on Non-alcoholic Fatty liver Disease in Obese Mice. Int. J. Chin. Med. 2021, 5(2), 22-28. doi: 10.11648/j.ijcm.20210502.11

    Copy | Download

    AMA Style

    Danny Ka-Ho Wong, Saisai Zhang, Gerald Wong, Ching Yan Serene Cheng, Regina Cheuk-Lam Lo, et al. Effect of a Herbal Formula Song Zhi Wan on Non-alcoholic Fatty liver Disease in Obese Mice. Int J Chin Med. 2021;5(2):22-28. doi: 10.11648/j.ijcm.20210502.11

    Copy | Download

  • @article{10.11648/j.ijcm.20210502.11,
      author = {Danny Ka-Ho Wong and Saisai Zhang and Gerald Wong and Ching Yan Serene Cheng and Regina Cheuk-Lam Lo and Fen Liu and Lung-Yi Mak and Peng Xiao and Wai-Kay Seto and Man Fung Yuen},
      title = {Effect of a Herbal Formula Song Zhi Wan on Non-alcoholic Fatty liver Disease in Obese Mice},
      journal = {International Journal of Chinese Medicine},
      volume = {5},
      number = {2},
      pages = {22-28},
      doi = {10.11648/j.ijcm.20210502.11},
      url = {https://doi.org/10.11648/j.ijcm.20210502.11},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcm.20210502.11},
      abstract = {Background: Effective treatment against non-alcoholic fatty liver disease (NAFLD) is lacking. Song Zhi Wan (SZW), a Chinese formulation medicine comprising eight herbal ingredients, has been demonstrated to confer a liver protective effect in chronic hepatitis C patients. We aimed to investigate the effect of SZW on NAFLD using a high-fat diet (HFD; 60% fat) induced obese mouse model. Methods: C57BL/6J mice were fed with HFD for 10 weeks, followed by daily oral administration of various dosages of SZW (low [n=6], normal [n=10], high [n=10]) or water (n=10) for 8 weeks. Another formulation of SZW (modified SZW), in which two ingredients were replaced by radish seed and barley, was tested. Serum total cholesterol and triglyceride levels, liver transaminases, and histologic steatosis were assessed. Results: At the end of experiment, the HFD-fed placebo mice had a mean increase in serum total cholesterol and triglyceride by 57.7% and 35.0%, respectively. HFD-fed mice receiving either SZW formulation had a smaller increase in serum total cholesterol (mean increase 7.9% – 39.4%) and a significant reduction in triglyceride (mean reduction 4.2% – 27.4%; P P=0.079). With an escalating dosage of original SZW, there was a decreasing proportion of mice with severe steatosis (P=0.013). Conclusion: SZW administration can attenuate hypercholesterolemia, reduce dyslipidemia and alleviate steatosis in HFD-induced obese mice.},
     year = {2021}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Effect of a Herbal Formula Song Zhi Wan on Non-alcoholic Fatty liver Disease in Obese Mice
    AU  - Danny Ka-Ho Wong
    AU  - Saisai Zhang
    AU  - Gerald Wong
    AU  - Ching Yan Serene Cheng
    AU  - Regina Cheuk-Lam Lo
    AU  - Fen Liu
    AU  - Lung-Yi Mak
    AU  - Peng Xiao
    AU  - Wai-Kay Seto
    AU  - Man Fung Yuen
    Y1  - 2021/04/26
    PY  - 2021
    N1  - https://doi.org/10.11648/j.ijcm.20210502.11
    DO  - 10.11648/j.ijcm.20210502.11
    T2  - International Journal of Chinese Medicine
    JF  - International Journal of Chinese Medicine
    JO  - International Journal of Chinese Medicine
    SP  - 22
    EP  - 28
    PB  - Science Publishing Group
    SN  - 2578-9473
    UR  - https://doi.org/10.11648/j.ijcm.20210502.11
    AB  - Background: Effective treatment against non-alcoholic fatty liver disease (NAFLD) is lacking. Song Zhi Wan (SZW), a Chinese formulation medicine comprising eight herbal ingredients, has been demonstrated to confer a liver protective effect in chronic hepatitis C patients. We aimed to investigate the effect of SZW on NAFLD using a high-fat diet (HFD; 60% fat) induced obese mouse model. Methods: C57BL/6J mice were fed with HFD for 10 weeks, followed by daily oral administration of various dosages of SZW (low [n=6], normal [n=10], high [n=10]) or water (n=10) for 8 weeks. Another formulation of SZW (modified SZW), in which two ingredients were replaced by radish seed and barley, was tested. Serum total cholesterol and triglyceride levels, liver transaminases, and histologic steatosis were assessed. Results: At the end of experiment, the HFD-fed placebo mice had a mean increase in serum total cholesterol and triglyceride by 57.7% and 35.0%, respectively. HFD-fed mice receiving either SZW formulation had a smaller increase in serum total cholesterol (mean increase 7.9% – 39.4%) and a significant reduction in triglyceride (mean reduction 4.2% – 27.4%; P P=0.079). With an escalating dosage of original SZW, there was a decreasing proportion of mice with severe steatosis (P=0.013). Conclusion: SZW administration can attenuate hypercholesterolemia, reduce dyslipidemia and alleviate steatosis in HFD-induced obese mice.
    VL  - 5
    IS  - 2
    ER  - 

    Copy | Download

Author Information
  • Department of Medicine, The University of Hong Kong, Hong Kong SAR; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong SAR

  • Department of Medicine, The University of Hong Kong, Hong Kong SAR

  • Department of Medicine, The University of Hong Kong, Hong Kong SAR

  • Department of Medicine, The University of Hong Kong, Hong Kong SAR

  • State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong SAR; Department of Pathology, The University of Hong Kong, Hong Kong SAR

  • Department of Gastroenterology and Hepatology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China

  • Department of Medicine, The University of Hong Kong, Hong Kong SAR; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong SAR

  • Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China

  • Department of Medicine, The University of Hong Kong, Hong Kong SAR; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong SAR; Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China

  • Department of Medicine, The University of Hong Kong, Hong Kong SAR; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong SAR

  • Sections